The Genetic Architecture of Variation in Humans and Dogs

Total Page:16

File Type:pdf, Size:1020Kb

The Genetic Architecture of Variation in Humans and Dogs THE GENETIC ARCHITECTURE OF VARIATION IN HUMANS AND DOGS by ELDON GOODWIN PRINCE Presented to the Faculty of the Graduate School of The University of Texas at Arlington in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY THE UNIVERSITY OF TEXAS AT ARLINGTON May 2014 Copyright © by Eldon Goodwin Prince 2014 All Rights Reserved ii Acknowledgements I am grateful for the guidance of my two advisors at UT Arlington, Trey Fondon and Jeff Demuth. I appreciate Jeff's mentoring and patience during the first two years of my degree. Trey created an intellectually demanding environment that has helped me to grow personally and professionally; I am grateful for his insights that heavily influence this work, and hope to have assimilated some of his patterns of critical thinking during the past few years. I thank my I-Engage students Emil Burdeos, Courtney Elledge, and Bethany Minter for their hard work and participating in many enlightening and fun conversations. Kristen Correll and Michael Chau contributed substantially to this work by helping to measure and genotype mixed-breed dogs. Shreyas Krishnan and many other graduate students and lab members have been genuine friends to me and my family; your kindness will not soon be forgotten. In addition, I thank Esther Betrán, André Pires da Silva, Todd Castoe, and Cédric Feschotte for valuable instruction and feedback. I also appreciate the Biology Department office staff for their assistance. Throughout this process I have received constant inspiration from my supremely patient and dedicated wife, Stephanie Prince. I could not have completed this work without her listening ear, lucid questions, and detailed proofreading. I thank my children Sophie, Elinor, and Goodwin for their inspiration and being willing to live so long without a backyard. I am grateful for the continuous support I have received from my siblings Edd, Patti, Sarabeth, John, Daniel, Joseph, Dallan, and Pauline. I am indebted to David and Pam Richards for their love and for letting me take their daughter to Texas. My parents Leon and Leah Prince have been pillars of strength and I thank them for their encouragement. Finally, I recognize the omnipresent role my grandparents Douglas and Beth Prince and Edd and Pauline Goodwin have played in shaping who I am. April 18, 2014 iii Abstract THE GENETIC ARCHITECTURE OF VARIATION IN HUMANS AND DOGS Eldon Goodwin Prince, Ph.D. The University of Texas at Arlington, 2014 Supervising Professor: John W. Fondon III, Ph.D. Genetic architecture is broadly defined as the structure of how genes come together to produce phenotypes. Primary aspects of genetic architecture include how many and which genes contribute to phenotypic variation. The genetic architecture of human height has been studied for over a century; indeed it is the classic quantitative trait with hundreds of contributing variants. As genome-wide studies of genetic architecture are extended beyond just humans, the genetic basis of polygenic traits like height can be compared between species. Such interspecies comparisons reveal how many of the same loci contribute to variation within each species. The extent to which the same loci contribute to intraspecific variation depends on species relatedness and reflects underlying constraints on genetic variability and variation. In this study genome-wide associations are compared between humans and dogs to estimate how many of the same loci contribute to intraspecific height variation. Due to the highly polygenic nature of height variation, one might predict that relatively few loci will be shared between species as distantly related as the human and dog. Contrary to this prediction, I find that at least 25 orthologous regions contribute to intraspecific height variation in humans and dogs, indicating perhaps less obvious constraints on genetic variability and variation. iv Height is decomposed in dogs using genome-wide associations to identify loci that are associated with limb, torso, and neck variation. To extend this approach, several height QTLs are correlated with bone measurements in an independent panel of mixed- breed dogs. The prevailing interpretation that morphological traits are genetically simple in dogs relative to humans is then tested. Central to the interpretation of genetic simplicity in dogs is the story of IGF1, a gene thought to explain the majority of size variation. The QTL effect size of IGF1 is tested in the aforementioned panel of mixed-breed dogs and I find that it explains much less variation than previously reported. This experiment and others call into question the Mendelian effect size previously attributed to IGF1 and the associated interpretation of genetic simplicity for dog morphology. One of the evolutionary forces that can impact the genetic architecture of traits is meiotic recombination. Preceding the exchange of genetic material between homologous chromosome pairs, double-strand breaks occur via proteins like Spo11 in yeast. Since all crossovers are the result of double-strand breaks, and these breaks are non-randomly distributed throughout the genome, many researchers have sought to understand the process that regulates where double-strand breaks occur. In addition, although not all double-strand breaks result in genetic crossover, the DNA repair process to rejoin them can be both biased and mutagenic. The protein PRDM9 is associated with almost all meiotic double-strand breaks in mice and is thought to play a similarly central role in humans, although the protein is absent in canids. Curiously, the loss of PRDM9 in the canid lineage also coincides with a genome-wide destabilization of repetitive GC content. I conclude this work with a study of the consequences of losing the meiotic recombination-associated protein PRDM9 and the mutagenic role this loss has likely had in shaping the canid lineage. v Table of Contents Acknowledgements .............................................................................................................iii Abstract .............................................................................................................................. iv List of Illustrations .............................................................................................................. ix List of Tables ......................................................................................................................xii Chapter 1 The Extent of Height QTL Sharing in Humans and Dogs .................................. 1 Introduction ..................................................................................................................... 1 Components of Genetic Architecture .............................................................................. 3 The Number of Loci That Contribute to Variation ....................................................... 3 When the Same Loci Contribute to Variation ............................................................. 4 Underlying Causative Mutations ................................................................................. 6 Setting Up the Comparison Between Humans and Dogs .............................................. 8 Human Height Variation ............................................................................................. 8 Dog Height Variation ................................................................................................ 15 History of Height in Humans ..................................................................................... 17 History of Height in Dogs .......................................................................................... 23 Genetic Architecture of Human Height ..................................................................... 26 Genetic Architecture of Dog Height .......................................................................... 28 Comparison of the Genetic Basis of Human and Dog Height Variation ....................... 29 Human Height QTLs ................................................................................................. 30 Dog Height QTLs ...................................................................................................... 30 Decomposition of Height .......................................................................................... 34 Functional Analysis of Dog Height QTLs.................................................................. 37 Selective Sweep Analysis of Dog Height QTLs ....................................................... 38 Identification of Shared Height QTLs ....................................................................... 40 vi Assessment of the Extent of QTL Sharing ............................................................... 43 Notable QTLs ........................................................................................................... 46 Why Some QTLs Are Missing .................................................................................. 48 Conclusion .................................................................................................................... 49 Chapter 2 Effect Size Distributions for Height in Humans and Dogs ................................ 51 Introduction ................................................................................................................... 51 The Effect Size Distribution of Human Height .............................................................. 52 The Problem of Missing Heritability .........................................................................
Recommended publications
  • Location Analysis of Estrogen Receptor Target Promoters Reveals That
    Location analysis of estrogen receptor ␣ target promoters reveals that FOXA1 defines a domain of the estrogen response Jose´ e Laganie` re*†, Genevie` ve Deblois*, Ce´ line Lefebvre*, Alain R. Bataille‡, Franc¸ois Robert‡, and Vincent Gigue` re*†§ *Molecular Oncology Group, Departments of Medicine and Oncology, McGill University Health Centre, Montreal, QC, Canada H3A 1A1; †Department of Biochemistry, McGill University, Montreal, QC, Canada H3G 1Y6; and ‡Laboratory of Chromatin and Genomic Expression, Institut de Recherches Cliniques de Montre´al, Montreal, QC, Canada H2W 1R7 Communicated by Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA, July 1, 2005 (received for review June 3, 2005) Nuclear receptors can activate diverse biological pathways within general absence of large scale functional data linking these putative a target cell in response to their cognate ligands, but how this binding sites with gene expression in specific cell types. compartmentalization is achieved at the level of gene regulation is Recently, chromatin immunoprecipitation (ChIP) has been used poorly understood. We used a genome-wide analysis of promoter in combination with promoter or genomic DNA microarrays to occupancy by the estrogen receptor ␣ (ER␣) in MCF-7 cells to identify loci recognized by transcription factors in a genome-wide investigate the molecular mechanisms underlying the action of manner in mammalian cells (20–24). This technology, termed 17␤-estradiol (E2) in controlling the growth of breast cancer cells. ChIP-on-chip or location analysis, can therefore be used to deter- We identified 153 promoters bound by ER␣ in the presence of E2. mine the global gene expression program that characterize the Motif-finding algorithms demonstrated that the estrogen re- action of a nuclear receptor in response to its natural ligand.
    [Show full text]
  • Tepzz¥ 6Z54za T
    (19) TZZ¥ ZZ_T (11) EP 3 260 540 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2017 Bulletin 2017/52 C12N 15/113 (2010.01) A61K 9/127 (2006.01) A61K 31/713 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 17000579.7 (22) Date of filing: 12.11.2011 (84) Designated Contracting States: • Sarma, Kavitha AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Philadelphia, PA 19146 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Borowsky, Mark PL PT RO RS SE SI SK SM TR Needham, MA 02494 (US) • Ohsumi, Toshiro Kendrick (30) Priority: 12.11.2010 US 412862 P Cambridge, MA 02141 (US) 20.12.2010 US 201061425174 P 28.07.2011 US 201161512754 P (74) Representative: Clegg, Richard Ian et al Mewburn Ellis LLP (62) Document number(s) of the earlier application(s) in City Tower accordance with Art. 76 EPC: 40 Basinghall Street 11840099.3 / 2 638 163 London EC2V 5DE (GB) (71) Applicant: The General Hospital Corporation Remarks: Boston, MA 02114 (US) •Thecomplete document including Reference Tables and the Sequence Listing can be downloaded from (72) Inventors: the EPO website • Lee, Jeannie T •This application was filed on 05-04-2017 as a Boston, MA 02114 (US) divisional application to the application mentioned • Zhao, Jing under INID code 62. San Diego, CA 92122 (US) •Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC). (54) POLYCOMB-ASSOCIATED NON-CODING RNAS (57) This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs.
    [Show full text]
  • A Private 16Q24.2Q24.3 Microduplication in a Boy with Intellectual Disability, Speech Delay and Mild Dysmorphic Features
    G C A T T A C G G C A T genes Article A Private 16q24.2q24.3 Microduplication in a Boy with Intellectual Disability, Speech Delay and Mild Dysmorphic Features Orazio Palumbo * , Pietro Palumbo , Ester Di Muro, Luigia Cinque, Antonio Petracca, Massimo Carella and Marco Castori Division of Medical Genetics, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013 Foggia, Italy; [email protected] (P.P.); [email protected] (E.D.M.); [email protected] (L.C.); [email protected] (A.P.); [email protected] (M.C.); [email protected] (M.C.) * Correspondence: [email protected]; Tel.: +39-088-241-6350 Received: 5 June 2020; Accepted: 24 June 2020; Published: 26 June 2020 Abstract: No data on interstitial microduplications of the 16q24.2q24.3 chromosome region are available in the medical literature and remain extraordinarily rare in public databases. Here, we describe a boy with a de novo 16q24.2q24.3 microduplication at the Single Nucleotide Polymorphism (SNP)-array analysis spanning ~2.2 Mb and encompassing 38 genes. The patient showed mild-to-moderate intellectual disability, speech delay and mild dysmorphic features. In DECIPHER, we found six individuals carrying a “pure” overlapping microduplication. Although available data are very limited, genomic and phenotype comparison of our and previously annotated patients suggested a potential clinical relevance for 16q24.2q24.3 microduplication with a variable and not (yet) recognizable phenotype predominantly affecting cognition. Comparing the cytogenomic data of available individuals allowed us to delineate the smallest region of overlap involving 14 genes. Accordingly, we propose ANKRD11, CDH15, and CTU2 as candidate genes for explaining the related neurodevelopmental manifestations shared by these patients.
    [Show full text]
  • Characterization of a 7.6-Mb Germline Deletion Encompassing the NF1 Locus and About a Hundred Genes in an NF1 Contiguous Gene Syndrome Patient
    European Journal of Human Genetics (2008) 16, 1459–1466 & 2008 Macmillan Publishers Limited All rights reserved 1018-4813/08 $32.00 www.nature.com/ejhg ARTICLE Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient Eric Pasmant*,1,2, Aure´lie de Saint-Trivier2, Ingrid Laurendeau1, Anne Dieux-Coeslier3, Be´atrice Parfait1,2, Michel Vidaud1,2, Dominique Vidaud1,2 and Ivan Bie`che1,2 1UMR745 INSERM, Universite´ Paris Descartes, Faculte´ des Sciences Pharmaceutiques et Biologiques, Paris, France; 2Service de Biochimie et de Ge´ne´tique Mole´culaire, Hoˆpital Beaujon AP-HP, Clichy, France; 3Service de Ge´ne´tique Clinique, Hoˆpital Jeanne de Flandre, Lille, France We describe a large germline deletion removing the NF1 locus, identified by heterozygosity mapping based on microsatellite markers, in an 8-year-old French girl with a particularly severe NF1 contiguous gene syndrome. We used gene-dose mapping with sequence-tagged site real-time PCR to locate the deletion end points, which were precisely characterized by means of long-range PCR and nucleotide sequencing. The deletion is located on chromosome arm 17q and is exactly 7 586 986 bp long. It encompasses the entire NF1 locus and about 100 other genes, including numerous chemokine genes, an attractive in silico-selected cerebrally expressed candidate gene (designated NUFIP2, for nuclear fragile X mental retardation protein interacting protein 2; NM_020772) and four microRNA genes. Interestingly, the centromeric breakpoint is located in intron 4 of the PIPOX gene (pipecolic acid oxidase; NM_016518) and the telomeric breakpoint in intron 5 of the GGNBP2 gene (gametogenetin binding protein 2; NM_024835) coding a transcription factor.
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma
    Research Article Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma Chunhua Lu,1 Tomas Bonome,3 Yang Li,1 Aparna A. Kamat,1 Liz Y. Han,1 Rosemarie Schmandt,1 Robert L. Coleman,1 David M. Gershenson,1 Robert B. Jaffe,4 MichaelJ. Birrer, 3 and AnilK. Sood 1,2 Departments of 1Gynecologic Oncology and 2Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas; 3Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland; and 4Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California Abstract the promise of such approaches. However, the full spectrum of Therapeutic strategies based on antiangiogenic approaches differences in the tumor vasculature compared with its normal are beginning to show great promise in clinical studies. counterpart is not known. Identification of additional targets on However, full realization of these approaches requires tumor endothelium may allow opportunities for developing new identification of key differences in gene expression between therapeutic approaches to inhibit angiogenesis in a tumor-specific endothelial cells from tumors versus their normal counter- manner. parts. Here, we examined gene expression differences in Higher levels of proangiogenic cytokines and angiogenesis are purified endothelial cells from 10invasive epithelial ovarian associated with an increased risk of metastasis and poor prognosis cancers and 5 normal ovaries using Affymetrix U133 Plus in ovarian cancer (5, 6). To date, a small number of breast, colon, 2.0microarrays. More than 400differentially expressed genes and brain cancers have been analyzed for gene expression changes were identified in tumor-associated endothelial cells.
    [Show full text]
  • Bioinformatic Analysis of Autism Positional Candidate Genes Using Biological Databases and Computational Gene Network Prediction
    Genes, Brain and Behavior (2003) 2: 303–320 Copyright # Blackwell Munksgaard 2003 Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction A. L. Yonan†,‡, A. A. Palmer†, K. C. Smith†, inform studies of autism, and to illustrate and explore I. Feldman†,††, H. K. Lee†, J. M. Yonan§, the increasing potential of bioinformatic approaches as † †,†† *,†,‡, S. G. Fischer , P. Pavlidis and T. C. Gilliam { a compliment to linkage analysis. Keywords: 17q, AGRE sample, autism, association studies, †Columbia Genome Center, Columbia University, New York, bioinformatics, candidate genes ‡ Department of Genetics and Development, Columbia University, Received 30 June 2003, revised 20 August 2003, accepted New York, for publication 21 August 2003 ¶Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, §Division of Molecular Genetics, Departments of Pediatrics and Medicine, Columbia University, New York, Autism is a pervasive neurodevelopmental disorder that ††Department of Biomedical Informatics, Columbia University, severely impairs development of normal social and emotional New York, USA interactions and related forms of communication. Disease *Corresponding author: T. C. Gilliam, Columbia Genome Center, symptoms characteristically include unusually restricted and 1150 St. Nicholas Avenue, Room 508, New York, NY 10032, USA. E-mail: [email protected] stereotyped patterns of behaviors and interests. Autism describes the most severe manifestation
    [Show full text]
  • Estudo Genético De Síndromes Associadas À Obesidade Estudo
    Mauren Fernanda Moller dos Santos Estudo genético de síndromes associadas à obesidade Dissertação apresentada ao Instituto de Biociências da Universidade de São Paulo, para a obtenção de Título de Mestre em Biologia/Genética. São Paulo 2014 Mauren Fernanda Moller dos Santos Estudo genético de síndromes associadas à obesidade Dissertação apresentada ao Instituto de Biociências da Universidade de São Paulo, para a obtenção de Título de Mestre em Biologia/Genética. Orientadora: Profa. Dra. Celia P. Koiffmann São Paulo 2014 ii Santos, Mauren Fernanda Moller dos Estudo genético de síndromes associadas à obesidade 174 pág. Dissertação de Mestrado - Instituto de Biociências da Universidade de São Paulo. Departamento de Genética e Biologia Evolutiva. 1 – Obesidade e/ou Hiperfagia 2 – Atraso do desenvolvimento neuropsicomotor 3 – Distúrbios de comportamento 4 – SNP-array 5 – Array-CGH 6 – Variação do número de cópias (CNV) Comissão Julgadora ______________________________ ______________________________ ______________________________ Profa. Dra. Celia P. Koifmann Orientadora iii AGRADECIMENTOS À Dra. Celia P. Koiffmann, pela oportunidade de participar de seu laboratório, pelos ensinamentos, por ter confiado em meu trabalho e pela sua paciência. Às Dras. Carla Rosenberg, Debora Bertola e Regina Célia Mingroni Netto, que participaram da minha qualificação e pelas suas sugestões. Aos pacientes e seus familiares que contribuíram para este trabalho, tornando possível o avanço dos estudos nesta área do conhecimento. À Cláudia, Carla, Amanda, Cris, Estela, Rose, Monica e Luceleni, por me ajudarem sempre que preciso, pela amizade e risadas. Especialmente à Cláudia por me ensinar citogenética e possibilitar que eu continue trabalhando com isso e à Carla pela grande colaboração nas técnicas e análises e pelas revisões de texto.
    [Show full text]
  • Pathway Analysis Within Multiple Human Ancestries Reveals Novel Signals for Epistasis in Complex Traits
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.24.312421; this version posted September 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 1 Pathway Analysis within Multiple Human Ancestries Reveals 2 Novel Signals for Epistasis in Complex Traits 3 1,2,y 2,3 2,4,*,y 1,2,*,y 4 Michael C. Turchin , Gregory Darnell , Lorin Crawford , and Sohini Ramachandran 5 1 Department of Ecology and Evolutionary Biology, Brown University, Providence, RI, 6 USA 7 2 Center for Computational Molecular Biology, Brown University, Providence, RI, USA 8 3 Institute for Computational and Experimental Research in Mathematics (ICERM), 9 Brown University, Providence, RI, USA 10 4 Microsoft Research New England, Cambridge, MA, USA 11 *: Authors Contributed Equally 12 y Corresponding E-mail: [email protected]; [email protected]; 13 [email protected] 14 Abstract 15 Genome-wide association (GWA) studies have identified thousands of significant genetic associations in 16 humans across a number of complex traits. However, the majority of these studies focus on linear additive 17 relationships between genotypic and phenotypic variation. Epistasis, or non-additive genetic interactions, 18 has been identified as a major driver of both complex trait architecture and evolution in multiple model 19 organisms; yet, this same phenomenon is not considered to be a significant factor underlying human 20 complex traits. There are two possible reasons for this assumption.
    [Show full text]
  • E-Mutpath: Computational Modelling Reveals the Functional Landscape of Genetic Mutations Rewiring Interactome Networks
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.262386; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. e-MutPath: Computational modelling reveals the functional landscape of genetic mutations rewiring interactome networks Yongsheng Li1, Daniel J. McGrail1, Brandon Burgman2,3, S. Stephen Yi2,3,4,5 and Nidhi Sahni1,6,7,8,* 1Department oF Systems Biology, The University oF Texas MD Anderson Cancer Center, Houston, TX 77030, USA 2Department oF Oncology, Livestrong Cancer Institutes, Dell Medical School, The University oF Texas at Austin, Austin, TX 78712, USA 3Institute For Cellular and Molecular Biology (ICMB), The University oF Texas at Austin, Austin, TX 78712, USA 4Institute For Computational Engineering and Sciences (ICES), The University oF Texas at Austin, Austin, TX 78712, USA 5Department oF Biomedical Engineering, Cockrell School of Engineering, The University oF Texas at Austin, Austin, TX 78712, USA 6Department oF Epigenetics and Molecular Carcinogenesis, The University oF Texas MD Anderson Science Park, Smithville, TX 78957, USA 7Department oF BioinFormatics and Computational Biology, The University oF Texas MD Anderson Cancer Center, Houston, TX 77030, USA 8Program in Quantitative and Computational Biosciences (QCB), Baylor College oF Medicine, Houston, TX 77030, USA *To whom correspondence should be addressed. Nidhi Sahni. Tel: +1 512 2379506; Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.262386; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Mental Retardation and Cardiovascular Malformations in NF1
    Downloaded from jmg.bmj.com on April 16, 2012 - Published by group.bmj.com 35 LETTER TO JMG Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2 *M Venturin, *P Guarnieri, F Natacci, M Stabile, R Tenconi, M Clementi, C Hernandez, P Thompson, M Upadhyaya, L Larizza, P Riva ............................................................................................................................... J Med Genet 2004;41:35–41. doi: 10.1136/jmg.2003.014761 eurofibromatosis type 1 (NF1 [MIM 162200]) is a common autosomal dominant disorder that affects Key points N1/3500 individuals and is caused by deletion or point mutations of NF1, a tumour suppressor gene mapping to N NF1 microdeletion syndrome is determined by haplo- 17q11.2. Its main features include cafe´au lait spots, axillary insufficiency of the NF1 gene and its flanking regions; and inguinal freckling, iris Lisch nodules, neurofibromas, and NF1 microdeleted patients show a more severe an increased risk of benign and malignant tumours, phenotype than observed in classical NF1 patients. particularly optic glioma, neurofibrosarcoma, malignant N The aim of this study was to verify the presence of 1 peripheral nerve sheath tumours (MPNSTs), and childhood specific clinical signs of NF1 microdeletion, by 2 myeloid leukaemia. combining clinical and genetic evidence from 92 Over 70% of NF1 germline mutations cause truncation or deleted patients, 14 newly characterised and 78 loss of the encoded protein. already published. Approximately
    [Show full text]
  • BANP (1524CT337.6.32): Sc-517314
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . BANP (1524CT337.6.32): sc-517314 BACKGROUND SOURCE BANP (BTG3 associated nuclear protein), also known as BEND1, SMARBP1 BANP (1524CT337.6.32) is a mouse monoclonal antibody raised against a or SMAR1, is a 519 amino acid protein that localizes to the nucleus and recombinant protein corresponding to amino acids 30-390 of BANP of human belongs to the BANP/SMAR1 family. Interacting with CDP and p53, BANP origin. functions to control V(D)J recombination during T-cell development, specifi - cally by binding to a scaffold/matrix DNA attachment region and repressing PRODUCT the enhancer function of TCR (T-cell receptor ). Additionally, BANP promotes β Each vial contains 100 µg IgG 1 kappa light chain in 1.0 ml of PBS with < 0.1% p53 serine phosphorylation, resulting in the subsequent nuclear accumulation sodium azide and 0.1% gelatin. of p53 and, ultimately, cell cycle arrest. BANP is down regulated in breast cancer cells, suggesting a role in tumor suppression. Three isoforms of BANP APPLICATIONS exist due to alternative splicing events. BANP (1524CT337.6.32) is recommended for detection of BANP of mouse, REFERENCES rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation [1-2 µg per 100-500 µg of total 1. Birot, A., Duret, L., Bartholin, L., Santalucia, B., Tigaud, I., Magaud, J. and protein (1 ml of cell lysate)]. Rouault, J. 2000. Identification and molecular analysis of BANP. Gene 253: 189-196. Suitable for use as control antibody for BANP siRNA (h): sc-72607, BANP siRNA (m): sc-72608, BANP shRNA Plasmid (h): sc-72607-SH, BANP shRNA 2.
    [Show full text]